G Sędek - Concepedia

Author

G Sędek

Novartis (Switzerland)

Also Known As

G S Sedek, G Sedek, G Sędek, G. S. Sedek, G. SEDEK, G. Sedek, G. Sédek, G. Sêdek, Greg Sedek, Greg Sędek

Publications

778

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis (United States)Novartis (France)Postgraduate School of Molecular Medicine Roche (Switzerland)

About

G Sędek is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	433
2	Social Sciences	2	2	20
3	Health Sciences	1	1	23
4	Allergy	1	1	113
5	Anesthesia	1	1	32

G Sędek

Publications

756

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients Gilbert Lefèvre, G Sędek, S. S. Jhee, Clinical Pharmacology & Therapeutics	2007	126
Pharmacokinetic‐pharmacodynamic interaction between the COMT inhibitor tolcapone and single‐dose levodopa. Jasper Dingemanse, Karin Jorga, G. Zürcher, British Journal of Clinical Pharmacology Molecular PharmacologyMedicinal ChemistryAllergyPharmacological StudyLevodopa Pharmacokinetics	1995	113
Multiple-dose clinical pharmacology of the catechol- O -methyl-transferase inhibitor tolcapone in elderly subjects Jasper Dingemanse, Karin Jorga, G. Zürcher, European Journal of Clinical Pharmacology Molecular PharmacologyMultiple-dose Clinical PharmacologyPharmacological StudyElderly SubjectsPharmacology	1996	63
Pharmacokinetics of a Rivastigmine Transdermal Patch Formulation in Healthy Volunteers: Relative Effects of Body Site Application Gilbert Lefèvre, G Sędek, Hsun‐Lun Aaron Huang, The Journal of Clinical Pharmacology	2007	60
Estimation of the Absolute Bioavailability of Rivastigmine in Patients with Mild to Moderate Dementia of the Alzheimer???s Type Mohammad Sharif Hossain, Stanford S. Jhee, Thomas Shiovitz, Clinical Pharmacokinetics Neurodegenerative DiseasesAlzheimer's DiseaseGeriatricsMedicineDementia	2002	59
Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly Subjects Gilbert Lefèvre, F. Pommier, G Sędek, The Journal of Clinical Pharmacology Translational MedicineHealthy Elderly SubjectsPharmacologyTopical DrugPharmacotherapy	2008	44
Effect of Tolcapone on Plasma Levodopa Concentrations after Coadministration with Levodopa/Carbidopa to Healthy Volunteers G Sędek, Karin Jorga, Monique Schmitt, Clinical Neuropharmacology	1997	40
The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation Karin Jorga, Bärbel Fotteler, G Sędek, Journal of Neurology Levodopa PharmacokineticsPharmacologyClinical PharmacologyPharmacotherapyMedicine	1998	35
Absorption of Rivastigmine from Different Regions of the Gastrointestinal Tract in Humans Lucy Lee, Mohammad Sharif Hossain, Yanfeng Wang, The Journal of Clinical Pharmacology Gastrointestinal PharmacologyGastroenterologyGi MetabolismGi TractPharmacotherapy	2004	32
Steady-State Pharmacokinetics of Rivastigmine in Patients with Mild to Moderate Alzheimer’s Disease Not Affected by Co-Administration of Memantine Joshua R. Shua‐Haim, Juanita Smith, Franck Picard, Clinical Drug Investigation Alzheimer's DiseasePharmacokinetic ModelingMedicineNeuropharmacologyClinical Pharmacology	2008	27

Page 1